PRESTIGE CONSUMER HEALTHCARE INC. Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount of $622.00 thousand for the 12-month period ending 2025-03-31, per its 10-K filed 2026-05-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsForeign · last filed 2026-05-14
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, tax credit, foreign, amount for the quarter ending 2021-03-31 was $5.40M.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, tax credit, foreign, amount for the quarter ending 2020-12-31 was $5.10M.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, tax credit, foreign, amount for the quarter ending 2020-09-30 was $5.10M.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2025 was $622.00K, a 30.03% decline from fiscal 2024.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2024 was $889.00K, a 31.46% decline from fiscal 2023.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2023 was $1.30M.
- PRESTIGE CONSUMER HEALTHCARE INC. effective income tax rate reconciliation, tax credit, foreign, amount for fiscal 2022 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount 6 month | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount 9 month | Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount 12 month |
|---|---|---|---|---|
| 2025-03-31 | $622.00K 10-K · filed 2026-05-14 | |||
| 2024-03-31 | $889.00K 10-K · filed 2026-05-14 | |||
| 2023-03-31 | $1.30M 10-K · filed 2025-05-09 | |||
| 2022-03-31 | $0.00 10-K · filed 2024-05-15 | |||
| 2021-03-31 | $5.40M 10-K · filed 2021-05-07 | $10.50M derived: sum of 2 quarters · filed 2021-05-07 | $15.60M derived: sum of 3 quarters · filed 2021-05-07 | $0.00 10-K · filed 2023-05-05 |
| 2020-12-31 | $5.10M 10-Q · filed 2021-02-04 | $10.20M derived: sum of 2 quarters · filed 2021-02-04 | ||
| 2020-09-30 | $5.10M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |